Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors von Hellmann, M.D., Kim, T.-W., Lee, C.B., Goh, B.-C., Miller, W.H., Oh, D.-Y., Jamal, R., Chee, C.-E., Chow, L.Q.M., Gainor, J.F., Desai, J., Solomon, B.J., Das Thakur, M., Pitcher, B., Foster, P., Hernandez, G., Wongchenko, M.J., Cha, E., Bang, Y.-J., Siu, L.L., Bendell, J.

Volltext

PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) von de Bono, J.S., De Giorgi, U., Massard, C., Bracarda, S., Nava Rodrigues, D., Kocak, I., Font, A., Arija, J. Arranz, Shih, K., Radavoi, G.D., Yu, W., Chan, W., Gendreau, S., Zhang, L., Riisnaes, R., Wongchenko, M.J., Maslyar, D., Jinga, V.

Volltext

Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation–positive melanoma receiving adjuvant vemuraf... von Ascierto, P.A., Lewis, K.D., Di Giacomo, A.M., Demidov, L., Mandalà, M., Bondarenko, I., Herbert, C., Mackiewicz, A., Rutkowski, P., Guminski, A., Simmons, B., Ye, C., Hooper, G., Wongchenko, M.J., Goodman, G.R., Yan, Y., Schadendorf, D.

Volltext

LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC) von de Bono, J.S., Bracarda, S., Sternberg, C.N., Chi, K.N., Olmos, D., Sandhu, S., Massard, C., Matsubara, N., Alekseev, B., Gafanov, R., Parnis, F., Buchschacher, G.L., Corrales, L., Borre, M., Vasconcelos Alves, G., Garcia, J., Harle-Yge, M-L., Chen, G., Wongchenko, M.J., Sweeney, C.

Volltext

Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafeni... von Yan, Y., Robert, C., Larkin, J., Ascierto, P.A., Dreno, B., Maio, M., Garbe, C., Chapman, P.B., Sosman, J.A., Wongchenko, M.J., Hsu, J.J., Chang, I., Caro, I., Rooney, I., McArthur, G., Ribas, A.

Volltext

First-line cobimetinib (C) + paclitaxel (P) in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and tumoral immune cell infiltration data from the... von Miles, D.W., Kim, S.-B., Velu, T., García-Saenz, J.A., Tan-Chiu, E., Sohn, J.H., Dirix, L., Vanˇásek, J., Borms, M.V., De Mingorance, J. Ilgado, Liu, M.-C., Moezi, M.M., Kozloff, M.F., Sparano, J.A., Xu, N., Yan, Y., Wongchenko, M.J., Simmons, B., McNally, V., Brufsky, A.

Volltext